A CCRK-EZH2 epigenetic circuitry drives hepatocarcinogenesis and associates with tumor recurrence and poor survival of patients

Journal of Hepatology

Volumn 62, Issue 5, 2015, Pages 1100-1111

  Feng, Hai ^a   Yu, Zhuo ^a   Tian, Yuan ^a   Lee, Ying Ying ^a   Li, May S ^a   Go, Minnie Y Y ^a   Cheung, Yue Sun ^a   Lai, Paul B S ^a   Chan, Andrew M L ^a   To, Ka Fai ^a   Chan, Henry L Y ^a   Sung, Joseph J Y ^a   Cheng, Alfred S L ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Androgen receptor; Chromatin modifications; Gender disparity; Hepatocellular carcinoma; Kinase

Indexed keywords

ALBUMIN; ANDROGEN RECEPTOR; BETA CATENIN; CELL CYCLE RELATED KINASE; GLYCOGEN SYNTHASE KINASE 3BETA; PHOSPHOTRANSFERASE; PROTEIN KINASE B; T CELL FACTOR PROTEIN; TRANSCRIPTION FACTOR E2F1; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG; CYCLIN DEPENDENT KINASE; CYCLIN-DEPENDENT KINASE-ACTIVATING KINASE; EZH2 PROTEIN, HUMAN; MICRORNA; POLYCOMB REPRESSIVE COMPLEX 2;

ALBUMIN BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING SITE; BODY WEIGHT; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; CARCINOGENESIS; CARCINOGENICITY; CELL GROWTH; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CLINICAL FEATURE; COLONY FORMATION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOWN REGULATION; ENZYME PHOSPHORYLATION; EPIGENETICS; GENE ACTIVATION; GENE CONTROL; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; IN VIVO STUDY; LIVER CARCINOGENESIS; LUCIFERASE ASSAY; MALE; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SITE DIRECTED MUTAGENESIS; SURVIVAL RATE; TRANSCRIPTION INITIATION; TUMOR VOLUME; UPREGULATION; ANIMAL; ECTOPIC EXPRESSION; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; LIVER CELL CARCINOMA; LIVER TUMOR; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR RECURRENCE;

ANIMALS; CARCINOGENESIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASES; ECTOPIC GENE EXPRESSION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; MICE; MICRORNAS; NEOPLASM RECURRENCE, LOCAL; POLYCOMB REPRESSIVE COMPLEX 2; SIGNAL TRANSDUCTION; SURVIVAL RATE;

EID: 84927784033     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2014.11.040     Document Type: Article

References (34)

1. H.B. El-Serag Epidemiology of viral hepatitis and hepatocellular carcinoma Gastroenterology 142 2012 e1261
2. Y. Tian, V.W. Wong, H.L. Chan, and A.S. Cheng Epigenetic regulation of hepatocellular carcinoma in non-alcoholic fatty liver disease Semin Cancer Biol 23 2013 471 482
3. A. Villanueva, and J.M. Llovet Targeted therapies for hepatocellular carcinoma Gastroenterology 140 2011 1410 1426
4. A. Villanueva, and J.M. Llovet Liver cancer in 2013: mutational landscape of HCC-the end of the beginning Nat Rev Clin Oncol 11 2014 73 74
5. Z.G. Han Functional genomic studies: insights into the pathogenesis of liver cancer Annu Rev Genomics Hum Genet 13 2012 171 205
6. Z. Yu, and A.S. Cheng Epigenetic deregulation of microRNAs: new opportunities to target oncogenic signaling pathways in hepatocellular carcinoma Curr Pharm Des 19 2013 1192 1200
7. L. Zender, A. Villanueva, V. Tovar, D. Sia, D.Y. Chiang, and J.M. Llovet Cancer gene discovery in hepatocellular carcinoma J Hepatol 52 2010 921 929
8. Y. Hoshida, S.M. Nijman, M. Kobayashi, J.A. Chan, J.P. Brunet, and D.Y. Chiang Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma Cancer Res 69 2009 7385 7392
9. J.K. Stauffer, A.J. Scarzello, J.B. Andersen, R.L. De Kluyver, T.C. Back, and J.M. Weiss Coactivation of AKT and beta-catenin in mice rapidly induces formation of lipogenic liver tumors Cancer Res 71 2011 2718 2727
10. E.S. Knudsen, P. Gopal, and A.G. Singal The changing landscape of hepatocellular carcinoma: etiology, genetics, and therapy Am J Pathol 184 2014 574 583
11. B. Vogelstein, N. Papadopoulos, V.E. Velculescu, S. Zhou, L.A. Diaz Jr., and K.W. Kinzler Cancer genome landscapes Science 339 2013 1546 1558
12. J.S. You, and P.A. Jones Cancer genetics and epigenetics: two sides of the same coin? Cancer Cell 22 2012 9 20
13. Z. Zhang Genomic landscape of liver cancer Nat Genet 44 2012 1075 1077
14. R. Margueron, and D. Reinberg The Polycomb complex PRC2 and its mark in life Nature 469 2011 343 349
15. D.P. Tsang, and A.S. Cheng Epigenetic regulation of signaling pathways in cancer: role of the histone methyltransferase EZH2 J Gastroenterol Hepatol 26 2011 19 27
16. M.L. Suva, N. Riggi, and B.E. Bernstein Epigenetic reprogramming in cancer Science 339 2013 1567 1570
17. W.L. Ma, H.C. Lai, S. Yeh, X. Cai, and C. Chang Androgen receptor roles in hepatocellular carcinoma, fatty liver, cirrhosis and hepatitis Endocr Relat Cancer 21 2014 R165 R182
18. H. Feng, A.S. Cheng, D.P. Tsang, M.S. Li, M.Y. Go, and Y.S. Cheung Cell cycle-related kinase is a direct androgen receptor-regulated gene that drives beta-catenin/T cell factor-dependent hepatocarcinogenesis J Clin Invest 121 2011 3159 3175
19. Z. Yu, Y.Q. Gao, H. Feng, Y.Y. Lee, M.S. Li, and Y. Tian Cell cycle-related kinase mediates viral-host signalling to promote hepatitis B virus-associated hepatocarcinogenesis Gut 63 2014 1793 1804
20. A.S. Cheng, S.S. Lau, Y. Chen, Y. Kondo, M.S. Li, and H. Feng EZH2-mediated concordant repression of Wnt antagonists promotes beta-catenin-dependent hepatocarcinogenesis Cancer Res 71 2011 4028 4039
21. A.P. Bracken, D. Pasini, M. Capra, E. Prosperini, E. Colli, and K. Helin EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer EMBO J 22 2003 5323 5335
22. E. Kim, M. Kim, D.H. Woo, Y. Shin, J. Shin, and N. Chang Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells Cancer Cell 23 2013 839 852
23. K. Xu, Z.J. Wu, A.C. Groner, H.H. He, C. Cai, and R.T. Lis EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent Science 338 2012 1465 1469
24. J.S. Lee, I.S. Chu, A. Mikaelyan, D.F. Calvisi, J. Heo, and J.K. Reddy Application of comparative functional genomics to identify best-fit mouse models to study human cancer Nat Genet 36 2004 1306 1311
25. P.K. Awuah, and S.P. Monga Cell cycle-related kinase links androgen receptor and beta-catenin signaling in hepatocellular carcinoma: why are men at a loss? Hepatology 55 2012 970 973
26. Z. Li, G. Tuteja, J. Schug, and K.H. Kaestner Foxa1 and Foxa2 are essential for sexual dimorphism in liver cancer Cell 148 2012 72 83
27. W.E. Naugler, T. Sakurai, S. Kim, S. Maeda, K. Kim, and A.M. Elsharkawy Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production Science 317 2007 121 124
28. M. Hatziapostolou, C. Polytarchou, E. Aggelidou, A. Drakaki, G.A. Poultsides, and S.A. Jaeger An HNF4alpha-miRNA inflammatory feedback circuit regulates hepatocellular oncogenesis Cell 147 2011 1233 1247
29. D. Iliopoulos, H.A. Hirsch, and K. Struhl An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation Cell 139 2009 693 706
30. T.A. Yap, A. Omlin, and J.S. de Bono Development of therapeutic combinations targeting major cancer signaling pathways J Clin Oncol 31 2013 1592 1605
31. T.L. Cha, B.P. Zhou, W. Xia, Y. Wu, C.C. Yang, and C.T. Chen Akt-mediated phosphorylation of EZH2 suppresses methylation of lysine 27 in histone H3 Science 310 2005 306 310
32. S.S. Ng, Y.T. Cheung, X.M. An, Y.C. Chen, M. Li, and G.H. Li Cell cycle-related kinase: a novel candidate oncogene in human glioblastoma J Natl Cancer Inst 99 2007 936 948
33. G. He, D. Dhar, H. Nakagawa, J. Font-Burgada, H. Ogata, and Y. Jiang Identification of liver cancer progenitors whose malignant progression depends on autocrine IL-6 signaling Cell 155 2013 384 396
34. J. Zhang, P.L. Yang, and N.S. Gray Targeting cancer with small molecule kinase inhibitors Nat Rev Cancer 9 2009 28 39